NVP2

NVP2 is a potent, ATP-competitive, and highly selective small molecule inhibitor of Cyclin-dependent kinase 9 (CDK9), with an IC50 in the low nanomolar range. Developed by Novartis, it serves as a critical tool compound for investigating the role of CDK9 in transcriptional regulation. CDK9, as part of the positive transcription elongation factor b (P-TEFb) complex, phosphorylates the C-terminal domain of RNA polymerase II to promote transcriptional elongation. Inhibition by NVP2 leads to a rapid decline in the mRNA levels of genes with short half-lives, including key oncogenes like MCL1 and MYC, subsequently triggering apoptosis in various cancer models, such as leukemia and triple-negative breast cancer. Due to its high selectivity over other CDKs, NVP2 is frequently used in preclinical research to differentiate the effects of CDK9 inhibition from those of other transcriptional kinases.